The evolution of CAR therapies across oncology and autoimmunity: mechanistic insights and therapeutic innovations
International Immunopharmacology · 2026-08 · 182 · 116867
DOI: 10.1016/j.intimp.2026.116867 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Immunopharmacology, 2026-08. Verfasst von Eslam E Abd El-Fattah und 3 weiteren Autor:innen. Beteiligte Einrichtung: Beckman Research Institute, City of Hope, Duarte, CA, USA; Department of Biochemistry, Faculty of Pharmacy, Delta University for Science and Technolo…. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Immunotherapy, Adoptive, Autoimmune Diseases, Neoplasms. Die Arbeit nennt 175 Literaturangaben.
Abstract (Originalsprache)
Chimeric antigen receptor (CAR)-engineered cellular therapies have progressed from early proof of concept into highly programmable platforms capable of mediating potent cytotoxicity and precise immune modulation. In oncology, successive CAR design has incorporated optimized costimulatory domains, cytokine-secreting modules, and gene-editing technologies to enhance efficacy and durability in hematologic malignancies. CD19- and BCMA-directed CAR-T cells induce deep and durable remissions in refractory B-cell leukemias, lymphomas, and multiple myeloma. Emerging strategies, including logic-gated CARs, synthetic Notch (SynNotch) circuits, and modular adaptor-based systems, aim to overcome antigen escape, reduce off-tumor toxicity, and extend efficacy to heterogeneous solid tumors. Concurrently, a conceptual shift has expanded CAR applications beyond cancer toward immune modulation in autoimmune diseases. CD19-directed CAR-T therapy has achieved deep B-cell depletion and clinical improvement in small early-phase studies (typically 5-18 patients) of systemic lupus erythematosus, inducing drug-free remission in some patients; however, randomized controlled trials are lacking and evidence remains preliminary. Antigen-specific approaches, including chimeric autoantibody receptor (CAAR)-T cells and CAR-engineered regulatory T-cells (CAR-Tregs), enable selective depletion of autoreactive B-cell clones or localized restoration of immune tolerance. These strategies are under investigation across systemic sclerosis, multiple sclerosis, myasthenia gravis, type 1 diabetes, inflammatory bowel disease, and rheumatoid arthritis. Collectively, advances in synthetic receptor engineering and translational application position CAR platforms as versatile, next-generation therapeutics across malignant and immune-mediated diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Beckman Research Institute, City of Hope, Duarte, CA, USA; Department of Biochemistry, Faculty of Pharmacy, Delta University for Science and Technology, Gamasa, Egypt.
- Research Institute for Science and Engineering (RISE), University of Sharjah, Sharjah, the United Arab Emirates.
- Research Institute for Medical and Health Sciences (RIMHS), University of Sharjah, Sharjah, the United Arab Emirates; Department of Medicinal Chemistry, College of Pharmacy, University of Sharjah, Sharjah, the United Ar…
- Beckman Research Institute, City of Hope, Duarte, CA, USA; Department of Translational Research & Cellular Therapeutics, Arthur Riggs Diabetes & Metabolism Research Institute, City of Hope National Medical Center, Duart…
Zitieren
APA
Abd El-Fattah, E. E., Hamdy, R., Soliman, S. S. M., & Husseiny, M. I. (2026). The evolution of CAR therapies across oncology and autoimmunity: mechanistic insights and therapeutic innovations. International Immunopharmacology, 182, 116867. https://doi.org/10.1016/j.intimp.2026.116867
Vancouver
Abd El-Fattah EE, Hamdy R, Soliman SSM, Husseiny MI. The evolution of CAR therapies across oncology and autoimmunity: mechanistic insights and therapeutic innovations. International Immunopharmacology. 2026;182:116867. doi:10.1016/j.intimp.2026.116867
BibTeX
@article{AbdElFattah2026,
author = {Abd El-Fattah, Eslam E and Hamdy, Rania and Soliman, Sameh S M and Husseiny, Mohamed I},
title = {The evolution of CAR therapies across oncology and autoimmunity: mechanistic insights and therapeutic innovations},
journal = {International Immunopharmacology},
year = {2026},
volume = {182},
pages = {116867},
doi = {10.1016/j.intimp.2026.116867}
}
EUVIMED